Calico (California Life Company) was founded by Alphabet in 2013 with a deliberately open-ended mandate: understand the biology of aging well enough to eventually influence it. That framing sets it apart from most companies on this list. Where a typical longevity biotech is organized around a specific mechanism (reprogramming, senolytics, gene therapy) and a path to a marketable therapy, Calico has functioned more like a basic-research institute with corporate resources behind it, studying comparative biology, genomics, and the fundamental pathways of cellular aging.
That long time horizon is both Calico's distinguishing feature and the thing that makes it harder to track from the outside. The company publishes research and partners with academic and pharmaceutical groups, but it has been comparatively quiet about specific therapeutic programs or timelines compared to venture-funded peers like Altos Labs or Retro Biosciences. For a field where hype outruns evidence more often than not, that reticence is arguably a feature: Calico's role in the ecosystem is closer to funding the science that other companies will eventually try to productize.
As AI-driven biology matures, large-scale, well-resourced basic-research efforts like Calico's are exactly the kind of environment where AI pattern-recognition across genomic and comparative-biology datasets can compound over a decade rather than a fundraising cycle. See the AI drug discovery article for the broader trend of AI being used to navigate biological complexity that would be intractable through pure human-led experimentation.